Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus MOXATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN HYDROCHLORIDE versus MOXATAG.
CIPROFLOXACIN HYDROCHLORIDE vs MOXATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Amoxicillin (extended-release) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors, leading to cell lysis and death via activation of autolytic enzymes.
500-750 mg orally every 12 hours; 400 mg intravenously every 8-12 hours.
775 mg orally once daily for 7 days.
None Documented
None Documented
Terminal half-life 4 hours (3-5 h) in normal renal function; prolonged to 5-10 h in mild-to-moderate renal impairment and >10 h in severe impairment (CrCl <30 mL/min).
The terminal elimination half-life is 1.0–1.5 hours in healthy adults; however, with the extended-release formulation (Moxatag), the effective half-life is prolonged to support once-daily dosing.
Renal: 50-70% unchanged drug; biliary/fecal: 15-25% (partly as metabolites).
Approximately 60% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 20% is excreted in feces via biliary elimination.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic